Catherine London, who has more than two decades of experience in the pharma and healthcare sectors, has joined biOasis Technologies as executive VP-corporate affairs and IR. She reports to CEO Mark Day.
|
|
Most recently, London did a two-year stint as corporate communications chief at Purdue Pharma, maker of Oxycontin.
Earlier, she held corporate and product PR positions at Alexion Pharmaceuticals and Boehringer Ingelheim and worked at communications firms Chandler Chicco and Ruder Finn.
At biOasis, London assumes a newly created post in charge of external communications, visibility, brand-building and financial communications.
CEO Day praised London as a “forward-thinking communications leader and collaborative relationship builder.”
biOasis, which is based in Vancouver, has developed treatments for neurological diseases such as brain cancers, neurodegenerative and metabolic diseases.

Catherine London
To make sure that the messages an annual meeting is supposed to deliver connect with their audiences, focus on the big story behind the complex data.
It’s not enough to simply be a good storyteller. Communicators now need to be explainers—making a range of complex subjects understandable to consumers.
Building awareness is no longer enough. Marketing and communications must ensure that when buyers begin researching a category, the company is visible, credible and differentiated.
With AI facing blowback from many audiences, it is becoming increasingly important to make sure that the human side of your communications comes through.
In a health landscape crowded with claims, brands earn trust by pairing credible proof with human stories, cultural relevance, and empowerment.



